Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 4/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | CASR | P41180 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | APEX1 | P27695 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.42 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9991224 | 0.83 | HPGD (0.58) | LOXL2HPGDMAPK1TSHRGAA | |
| SCHEMBL17146483 | 0.83 | HPGD (0.58) | LOXL2HPGDMAPK1TSHRGAA | |
| SCHEMBL7363930 | 0.82 | LOXL2 (0.60) | LOXL2HPGDMAPK1TSHRGAA | |
| SCHEMBL485998 | 0.81 | HPGD (0.64) | LOXL2HPGDMAPK1TSHRGAA | |
| SCHEMBL17947424 | 0.81 | HPGD (0.64) | LOXL2HPGDMAPK1TSHRGAA | |
| SCHEMBL12085830 | 0.81 | HPGD (0.64) | LOXL2HPGDMAPK1TSHRGAA | |
| SCHEMBL8319172 | 0.81 | LOXL2 (0.62) | LOXL2HPGDMAPK1TSHRGAA | |
| SCHEMBL29690505 | 0.81 | HPGD (0.55) | LOXL2HPGDMAPK1TSHRGAA | |
| SCHEMBL10729448 | 0.80 | LOXL2 (0.66) | LOXL2HPGDMAPK1TSHRGAA | |
| SCHEMBL6363260 | 0.79 | HPGD (0.54) | LOXL2HPGDMAPK1TSHRGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115515685-B | EIF4E inhibitors and uses thereof | 皮克医疗公司 | 2025-04-08 | — | — | CN | disclosed |
| US-12157731-B2 | EIF4E inhibitors and uses thereof | PIC Therapeutics, Inc. (US) | 2024-12-03 | — | — | US | disclosed |
| US-20230399322-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. | 2023-12-14 | — | — | US | disclosed |
| US-20230399322-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. | 2023-12-14 | — | — | US | disclosed |
| US-20230399322-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. | 2023-12-14 | — | — | US | disclosed |
| US-11753403-B2 | EIF4E inhibitors and uses thereof | PIC Therapeutics, Inc. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753403-B2 | EIF4E inhibitors and uses thereof | PIC Therapeutics, Inc. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753403-B2 | EIF4E inhibitors and uses thereof | PIC Therapeutics, Inc. (US) | 2023-09-12 | — | — | US | disclosed |
| US-20220356178-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. | 2022-11-10 | — | — | US | disclosed |
| WO-2021178488-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. (US) | 2021-09-10 | — | — | WO | disclosed |
| EP-0635018-B1 | 4-(1H-2-METHYLIMIDAZO[4,5-c]PYRIDINYLMETHYL)PHENYLSULPHONAMIDE DERIVATIVES AS ANTAGONISTS OF PAF | BRITISH BIO TECHNOLOGY (GB) | 1999-12-22 | — | — | EP | disclosed |
| US-5516783-A | PLATELET ACTIVATING FACTOR | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1996-05-14 | — | — | US | disclosed |
| EP-0635018-A1 | 4-(1H-2-METHYLIMIDAZO 4,5-c]PYRIDINYLMETHYL)PHENYLSULPHONAMIDE DERIVATIVES AS ANTAGONISTS OF PAF | BRITISH BIO-TECHNOLOGY LIMITED (GB) | 1995-01-25 | — | — | EP | disclosed |
| WO-1993016075-A1 | 4-(1H-2-METHYLIMIDAZO[4,5-c]PYRIDINYLMETHYL)PHENYLSULPHONAMIDE DERIVATIVES AS ANTAGONISTS OF PAF | BRITISH BIO-TECHNOLOGY LIMITED (GB) | 1993-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230399322-A1 | EIF4E INHIBITORS AND USES THEREOF | EIF4E, EIF4EBP1, EIF4A1 | LOXL2 4131/4885HPGD 4535/4885MAPK1 1701/4885 |
| US-12157731-B2 | EIF4E inhibitors and uses thereof | EIF4E, EIF4EBP1, EIF4A1 | LOXL2 4131/4885HPGD 4535/4885MAPK1 1701/4885 |
| US-11753403-B2 | EIF4E inhibitors and uses thereof | EIF4E, EIF4EBP1, EIF4A1 | LOXL2 4131/4885HPGD 4535/4885MAPK1 1701/4885 |
| US-20220356178-A1 | EIF4E INHIBITORS AND USES THEREOF | EIF4E, EIF4EBP1, EIF4A1 | LOXL2 4131/4885HPGD 4535/4885MAPK1 1701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.